Picard Medical Reports 12.5% Revenue Growth for FY 2025
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 8 hours ago
0mins
Should l Buy PMI?
Source: seekingalpha
- Financial Performance: Picard Medical reported FY 2025 revenue of $4.94 million, reflecting a 12.5% year-over-year growth, indicating steady market performance despite the relatively low revenue base.
- Cash Position: As of December 31, 2025, the company had $11.5 million in cash, cash equivalents, and restricted cash, a significant increase from $0.1 million in 2024, showcasing improved financial management.
- Operating Cash Flow: The net cash used in operating activities was $(15.7) million, while net cash provided by financing activities was $27.1 million, highlighting successful financing efforts but raising concerns about operational efficiency.
- Future Outlook: Picard Medical plans to continue investing in commercialization, manufacturing scale, and product development, indicating that additional capital will be required to support operations and execute the company’s business plan, reflecting confidence in future growth.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy PMI?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on PMI
About PMI
Picard Medical, Inc. is a holding company that owns a 100% interest in SynCardia Systems, LLC (SynCardia). SynCardia is a medical technology company that manufactures and sells the only United States Food and Drug Administration (FDA) and Health Canada-approved implantable total artificial heart (SynCardia TAH). The SynCardia TAH is a biventricular replacement device that consists of the SynCardia TAH implant, an external pneumatic driver that delivers precisely calibrated pulses of air to drive the implant, and drivelines that connect the driver to the implant. The SynCardia TAH implant is a system that consists of two independent artificial ventricles which are powered by an external pneumatic driver. Each artificial ventricle is made of a semi-rigid polyurethane housing and a rigid polyurethane base, with a four-layer flexible polyurethane diaphragm separating the blood chamber from the air chamber.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Picard Medical Reports 12.5% Revenue Growth for FY 2025
- Financial Performance: Picard Medical reported FY 2025 revenue of $4.94 million, reflecting a 12.5% year-over-year growth, indicating steady market performance despite the relatively low revenue base.
- Cash Position: As of December 31, 2025, the company had $11.5 million in cash, cash equivalents, and restricted cash, a significant increase from $0.1 million in 2024, showcasing improved financial management.
- Operating Cash Flow: The net cash used in operating activities was $(15.7) million, while net cash provided by financing activities was $27.1 million, highlighting successful financing efforts but raising concerns about operational efficiency.
- Future Outlook: Picard Medical plans to continue investing in commercialization, manufacturing scale, and product development, indicating that additional capital will be required to support operations and execute the company’s business plan, reflecting confidence in future growth.
See More
Class Action Lawsuit Filed Against Picard Medical, Inc.
- Lawsuit Background: Levi & Korsinsky LLP has notified investors in Picard Medical, Inc. (NYSE:PMI) of a class action securities lawsuit due to alleged fraud occurring between September 2, 2025, and October 31, 2025, aimed at recovering losses for affected investors.
- Fraud Allegations: The complaint alleges that defendants engaged in a fraudulent stock promotion scheme involving misinformation on social media and impersonated financial professionals, which led to significant losses for investors during a price inflation campaign.
- Insider Trading: It further claims that insiders and affiliates used offshore or nominee accounts to facilitate coordinated share dumping, exacerbating market manipulation and rendering the company's positive statements materially misleading.
- Investor Rights: Affected investors have until April 3, 2026, to request appointment as lead plaintiff, with participation in the lawsuit at no cost, as Levi & Korsinsky LLP commits to providing legal support without any out-of-pocket expenses for investors.
See More
Class Action Lawsuit Filed Against Picard Medical, Inc.
- Lawsuit Background: Bragar Eagel & Squire, P.C. has announced a class action lawsuit against Picard Medical, Inc. on behalf of investors who purchased securities between September 2, 2025, and October 31, 2025, indicating significant legal risks for the company.
- Fraud Allegations: The complaint alleges that Picard failed to disclose its involvement in a fraudulent stock promotion scheme utilizing social media misinformation, resulting in investor losses and highlighting serious deficiencies in corporate governance and transparency.
- Stock Price Crash: On October 24, 2025, Picard's stock price plummeted by 70%, from $13.30 to $3.99, and has since continued to decline to approximately $2.00, reflecting extreme market pessimism regarding the company's future prospects.
- Investor Action: Investors must apply by April 3, 2026, to be appointed as lead plaintiff in the lawsuit, indicating that the legal challenges faced by the company may impact its future financing and market trust.
See More
Class Action Notice for Picard Medical Securities Purchasers
- Class Action Notice: Rosen Law Firm reminds investors who purchased Picard Medical (NYSE American: PMI) securities between September 2 and October 31, 2025, to apply as lead plaintiffs by April 13, 2026, to participate in the class action without any out-of-pocket fees.
- Lawsuit Background: The lawsuit alleges that Picard Medical failed to disclose significant adverse facts related to its business and securities trading during the class period, including a fraudulent stock promotion scheme involving social media misinformation and insider share dumping, misleading investors about the company's true situation.
- Law Firm's Credentials: Rosen Law Firm specializes in securities class actions and has recovered over $438 million for investors in 2019 alone, being ranked first in 2017 for the number of securities class action settlements, showcasing its expertise and success in this field.
- Investor Guidance: Investors are advised to select qualified counsel with a proven track record, avoiding firms that merely act as intermediaries, to ensure their rights are effectively protected in the class action process.
See More
Reminder of Class Action Lawsuit for Picard Medical Investors
- Stock Price Crash: On October 23, 2025, Picard Medical's stock plummeted approximately 70% during after-hours trading, dropping from $13.20 to $3.99 per share, resulting in significant losses for investors and reflecting a sharp decline in market confidence in the company.
- Fraudulent Promotion: Investigations revealed that Picard's stock was the target of an illicit social media promotion scheme, where impersonators of real financial advisors falsely touted the stock in online forums and social media, artificially inflating its price and exacerbating investor loss risks.
- Lawsuit Allegations: The class action lawsuit alleges that throughout the class period, defendants made materially false and misleading statements and failed to disclose adverse facts about the company's business and prospects, leading to investor misunderstandings that could impact future legal liabilities.
- Investor Action Required: Investors must file a motion to be appointed as lead plaintiff in this class action by April 3, 2026, to pursue claims for loss recovery under federal securities laws, highlighting the importance of legal proceedings in protecting investor rights.
See More
Faruqi & Faruqi Investigates Securities Fraud at Picard Medical
- Securities Fraud Investigation: Faruq & Faruqi LLP is investigating potential securities fraud involving Picard Medical, urging investors who suffered losses between September 2, 2025, and October 31, 2025, to contact them before the April 13, 2026, deadline to seek lead plaintiff status.
- Stock Price Plunge: On October 24, 2025, Picard Medical's shares plummeted from $13.20 on October 23 to $5.31, a drop of $7.89 or approximately 59.8%, marking one of the most significant single-day declines since the company's IPO, indicating severe market concerns about its financial health.
- False Promotion Allegations: The complaint alleges that Picard Medical and its executives violated federal securities laws by failing to disclose involvement in a fraudulent stock promotion scheme and insider trading activities, which may have led to substantial investor losses.
- Lead Plaintiff Criteria: The court-appointed lead plaintiff must be the investor with the largest financial interest in the relief sought, and Faruqi & Faruqi encourages anyone with information, including whistleblowers and former employees, to contact them to assist in the case's progress.
See More
Picard Medical Reports 12.5% Revenue Growth for FY 2025
- Financial Performance: Picard Medical reported FY 2025 revenue of $4.94 million, reflecting a 12.5% year-over-year growth, indicating steady market performance despite the relatively low revenue base.
- Cash Position: As of December 31, 2025, the company had $11.5 million in cash, cash equivalents, and restricted cash, a significant increase from $0.1 million in 2024, showcasing improved financial management.
- Operating Cash Flow: The net cash used in operating activities was $(15.7) million, while net cash provided by financing activities was $27.1 million, highlighting successful financing efforts but raising concerns about operational efficiency.
- Future Outlook: Picard Medical plans to continue investing in commercialization, manufacturing scale, and product development, indicating that additional capital will be required to support operations and execute the company’s business plan, reflecting confidence in future growth.
See More
Class Action Lawsuit Filed Against Picard Medical, Inc.
- Lawsuit Background: Levi & Korsinsky LLP has notified investors in Picard Medical, Inc. (NYSE:PMI) of a class action securities lawsuit due to alleged fraud occurring between September 2, 2025, and October 31, 2025, aimed at recovering losses for affected investors.
- Fraud Allegations: The complaint alleges that defendants engaged in a fraudulent stock promotion scheme involving misinformation on social media and impersonated financial professionals, which led to significant losses for investors during a price inflation campaign.
- Insider Trading: It further claims that insiders and affiliates used offshore or nominee accounts to facilitate coordinated share dumping, exacerbating market manipulation and rendering the company's positive statements materially misleading.
- Investor Rights: Affected investors have until April 3, 2026, to request appointment as lead plaintiff, with participation in the lawsuit at no cost, as Levi & Korsinsky LLP commits to providing legal support without any out-of-pocket expenses for investors.
See More
Class Action Lawsuit Filed Against Picard Medical, Inc.
- Lawsuit Background: Bragar Eagel & Squire, P.C. has announced a class action lawsuit against Picard Medical, Inc. on behalf of investors who purchased securities between September 2, 2025, and October 31, 2025, indicating significant legal risks for the company.
- Fraud Allegations: The complaint alleges that Picard failed to disclose its involvement in a fraudulent stock promotion scheme utilizing social media misinformation, resulting in investor losses and highlighting serious deficiencies in corporate governance and transparency.
- Stock Price Crash: On October 24, 2025, Picard's stock price plummeted by 70%, from $13.30 to $3.99, and has since continued to decline to approximately $2.00, reflecting extreme market pessimism regarding the company's future prospects.
- Investor Action: Investors must apply by April 3, 2026, to be appointed as lead plaintiff in the lawsuit, indicating that the legal challenges faced by the company may impact its future financing and market trust.
See More
Class Action Notice for Picard Medical Securities Purchasers
- Class Action Notice: Rosen Law Firm reminds investors who purchased Picard Medical (NYSE American: PMI) securities between September 2 and October 31, 2025, to apply as lead plaintiffs by April 13, 2026, to participate in the class action without any out-of-pocket fees.
- Lawsuit Background: The lawsuit alleges that Picard Medical failed to disclose significant adverse facts related to its business and securities trading during the class period, including a fraudulent stock promotion scheme involving social media misinformation and insider share dumping, misleading investors about the company's true situation.
- Law Firm's Credentials: Rosen Law Firm specializes in securities class actions and has recovered over $438 million for investors in 2019 alone, being ranked first in 2017 for the number of securities class action settlements, showcasing its expertise and success in this field.
- Investor Guidance: Investors are advised to select qualified counsel with a proven track record, avoiding firms that merely act as intermediaries, to ensure their rights are effectively protected in the class action process.
See More
Reminder of Class Action Lawsuit for Picard Medical Investors
- Stock Price Crash: On October 23, 2025, Picard Medical's stock plummeted approximately 70% during after-hours trading, dropping from $13.20 to $3.99 per share, resulting in significant losses for investors and reflecting a sharp decline in market confidence in the company.
- Fraudulent Promotion: Investigations revealed that Picard's stock was the target of an illicit social media promotion scheme, where impersonators of real financial advisors falsely touted the stock in online forums and social media, artificially inflating its price and exacerbating investor loss risks.
- Lawsuit Allegations: The class action lawsuit alleges that throughout the class period, defendants made materially false and misleading statements and failed to disclose adverse facts about the company's business and prospects, leading to investor misunderstandings that could impact future legal liabilities.
- Investor Action Required: Investors must file a motion to be appointed as lead plaintiff in this class action by April 3, 2026, to pursue claims for loss recovery under federal securities laws, highlighting the importance of legal proceedings in protecting investor rights.
See More
Faruqi & Faruqi Investigates Securities Fraud at Picard Medical
- Securities Fraud Investigation: Faruq & Faruqi LLP is investigating potential securities fraud involving Picard Medical, urging investors who suffered losses between September 2, 2025, and October 31, 2025, to contact them before the April 13, 2026, deadline to seek lead plaintiff status.
- Stock Price Plunge: On October 24, 2025, Picard Medical's shares plummeted from $13.20 on October 23 to $5.31, a drop of $7.89 or approximately 59.8%, marking one of the most significant single-day declines since the company's IPO, indicating severe market concerns about its financial health.
- False Promotion Allegations: The complaint alleges that Picard Medical and its executives violated federal securities laws by failing to disclose involvement in a fraudulent stock promotion scheme and insider trading activities, which may have led to substantial investor losses.
- Lead Plaintiff Criteria: The court-appointed lead plaintiff must be the investor with the largest financial interest in the relief sought, and Faruqi & Faruqi encourages anyone with information, including whistleblowers and former employees, to contact them to assist in the case's progress.
See More
